Overview
GT Bio builds Deliveromics, a platform that creates an in vivo drug delivery atlas by combining spatial biology, machine learning, and targeted conjugates to enable scalable, cell-type-specific delivery in living organisms. It uses high-throughput in vivo screening to collect data and predict the design of delivery vehicles like ligand-conjugated lipid nanoparticles, aiming to shorten timelines and reduce costs vs traditional methods. The platform differentiates itself by tightly integrating spatial context with AI to model delivery across brain, immune system, and other tissues, offering a data-driven path to precision therapies and enabling collaborators in academia and industry to accelerate their research and development. GT Bio’s goal is to enable scalable, cell-type-specific precision therapies by providing delivery solutions and an adaptable platform for researchers and companies.
Work here?Claim your company
Simplify's take
What believers are saying
- ARPA-H awarded up to $600K on March 2, 2026, validating the platform.
- SCBIO selected GT Bio for its Drive Accelerator on April 15, 2026.
- The October 13, 2026 website update and active hiring signal continuing partner interest.
What critics are saying
- GT Bio reports no commercial revenue and depends on grant-funded R&D in 2026.
- If Deliveromics misses reproducibility, pharma partners abandon it and GT Bio becomes a service lab.
- Clinical/translation risk is existential: without validated delivery wins by 2027, fundraising collapses.
What makes GT Bio unique
- GT Bio’s Deliveromics couples in vivo multiplexed screening with AI-trained delivery design.
- Edward Boyden’s scientific brand and MIT-linked founders strengthen credibility with partners.
- The platform targets brain, immune, and other tissues using ligand-conjugated lipid nanoparticles.
Help us improve and share your feedback! Did you find this helpful?